# OnCo record idea-tnbc-her2-ultralow-testing-uptake (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tnbc-her2-ultralow-testing-uptake/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tnbc-her2-ultralow-testing-uptake" ;
  schema:name "Reflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan"@en ;
  schema:description "About a third of triple-negative tumours are HER2-low and so eligible for trastuzumab deruxtecan, but the difference between a HER2 score of 0 and 1+ is the one pathologists agree on least, and most triple-negative tumours were scored before the label mattered. Re-scoring archived slides with digital help when a patient relapses would find the eligible third."@en ;
  schema:url <https://onco.cc/ideas/idea-tnbc-her2-ultralow-testing-uptake/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/33397968> ;
  onco:tag "tnbc-evidence" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/terms/ihc/> ;
  onco:trials <https://onco.cc/trials/destiny-breast04/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-knowledge-diffusion/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-destiny-breast04-nat-med-2025-update/> .